All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

The CAR T-cell therapy lisocabtagene maraleucel induced complete responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia.

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

The risk for developing hepatocellular carcinoma appears to increase with subsequent generations for Americans of Mexican descent, according to findings from a study of US-born Hispanics/Latinos living in Los Angeles, California.

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

January 26th 2023

Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.

NCCN Recommends Sodium Thiosulfate to Reduce the Risk for Cisplatin-Induced Hearing Loss in Pediatric Patients

January 25th 2023

Fennec Pharmaceuticals announced an update to the National Comprehensive Cancer Network’s practice guidelines for Adolescent and Young Adult Oncology, calling for the use of sodium thiosulfate injection to reduce the risk for ototoxicity in pediatric patients receiving cisplatin.

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Maintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant after induction therapy, according to an unplanned interim analysis of the phase 3 ATLAS trial.

Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer

January 25th 2023

The combination of avutometinib and defactinib elicited responses in patients with recurrent low-grade serous ovarian cancer, according to data from a planned interim analysis of the registration-directed phase 2 RAMP-201 trial.

American Oncology Network Announces Brad Prechtl’s Retirement After 20 Years of Dedicated Service to Community Oncology

January 25th 2023

The American Oncology Network, LLC announced Brad Prechtl’s retirement as President and Chief Development Officer effective January 1, 2023.

KEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility

January 25th 2023

Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility.

Pembrolizumab Plus Standard Chemotherapy Improves OS in Biliary Tract Cancer

January 25th 2023

Adding the PD-1 inhibitor pembrolizumab to gemcitabine and cisplatin led to a significant improvement in overall survival compared with gemcitabine and cisplatin alone as first-line therapy in patients with advanced or unresectable biliary tract cancer.

Practices Should Redouble Efforts to Help Patients Address Financial Toxicity

January 25th 2023

Although fully addressing the financial hardship of patients with cancer requires a complex, multifaceted approach, even small changes may ease these burdens and improve patient outcomes.

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Bavituximab in combination with pembrolizumab produced responses in patients with previously untreated advanced hepatocellular carcinoma.

Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST

January 24th 2023

Second-line ripretinib produced a clinical benefit in patients with advanced gastrointestinal stromal tumor harboring KIT exon 11 and 17/18 mutations who progressed on or were intolerant to imatinib.

CTX-009 Plus Paclitaxel Produces Responses in Advanced Biliary Tract Cancer

January 24th 2023

The addition of the novel bispecific antibody CTX-009 to paclitaxel showed promising efficacy in the second- and third-line settings for patients with advanced biliary tract cancer.

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Autologous stem cell transplant had no effect on real-world time to next treatment and overall survival compared with maintenance rituximab following induction with bendamustine and rituximab or R-CHOP, for patients with mantle cell lymphoma according to findings from a retrospective study.

Novel Combinations Promote Individualized Care in Bladder and Prostate Cancer

January 24th 2023

Alicia Morgans, MD, MPH, discussed the evolving role of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, investigational immunotherapy combinations in urothelial cancer, and how antibody-drug conjugates provide a unique means of delivering toxic agents directly to tumors.

CAR-T-cell Shows Promise in Patients With Lymphoma of the Brain and Spinal Cord in Early Trial

January 24th 2023

A CAR-T-cell therapy known as axicabtagene ciloleucel is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord.

FDA Receives Premarket Approval Application for Noninvasive CRC Screening Test

January 24th 2023

Geneoscopy has submitted a premarket approval application to the FDA for a noninvasive, stool-based, at-home screening test to detect colorectal cancer and advanced adenomas in average-risk individuals.

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.

FDA Grants Priority Review to Avapritinib in Indolent Systemic Mastocytosis

January 23rd 2023

The FDA has granted a priority review to the supplemental new drug application (sNDA) to avapritinib for the treatment of adult patients with indolent systemic mastocytosis.

Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis

January 23rd 2023

First-line ruxolitinib plus pegylated interferon alpha 2a demonstrated durable spleen volume reduction in patients with myelofibrosis.